NCT06121765 2023-11-08
Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI
Assiut University
Unknown
Clinical Trials
15 trialsNCT03933852 2023-05-10
Ponderosa
University of Jena
Unknown
NCT05638763 2022-12-06
Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Unknown
NCT05543161 2022-09-16
"Peripheral Blood Dipeptidylpeptidase IV (CD26) Positive Leukemic Stem Cells in Chronic Myeloid Leukemia as a Diagnostic Marker"
Sohag University
Unknown
NCT05311943 2022-07-29
Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.
Shenzhen Second People's Hospital
Phase 3 Unknown
NCT03942094 2022-03-16
Nilotinib for First-line Newly Diagnosed CML-CP Patients
Shenzhen Second People's Hospital
Phase 3 Unknown
NCT02767063 2020-08-07
ACTIW
Versailles Hospital
Phase 1/2 Unknown
NCT01619761 2020-02-11
NK Cells in Cord Blood Transplantation
M.D. Anderson Cancer Center
Phase 1 Unknown
NCT03907670 2019-09-30
Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor
Assiut University
Unknown
NCT03131986 2018-06-11
Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia
The University of Hong Kong
Unknown
NCT03515018 2018-05-22
HU
First Affiliated Hospital of Harbin Medical University
Phase 3 Unknown
NCT03239886 2018-03-23
Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log
University of Sao Paulo General Hospital
Phase NA Unknown
NCT01887561 2013-06-27
Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial
Kanto CML Study Group
Phase 2 Unknown
NCT01227135 2011-11-30
Imatinib Mesylate With or Without Hydroxychloroquine in Treating Patients With Chronic Myeloid Leukemia
University of Glasgow
Phase 2 Unknown
NCT01464411 2011-11-03
D-First
Kanto CML Study Group
Unknown